Peer Review reports
From: Anti-tumor effects of mevalonate pathway inhibition in ovarian cancer
| Original Submission | ||
|---|---|---|
| 14 Apr 2020 | Submitted | Original manuscript |
| 5 May 2020 | Author responded | Author comments - Andy Göbel |
| Resubmission - Version 2 | ||
| 5 May 2020 | Submitted | Manuscript version 2 |
| 6 Jun 2020 | Reviewed | Reviewer Report |
| 16 Jun 2020 | Reviewed | Reviewer Report - Prabhakar Pitta Venkata |
| 26 Jun 2020 | Author responded | Author comments - Andy Göbel |
| Resubmission - Version 3 | ||
| 26 Jun 2020 | Submitted | Manuscript version 3 |
| 1 Jul 2020 | Author responded | Author comments - Andy Göbel |
| Resubmission - Version 4 | ||
| 1 Jul 2020 | Submitted | Manuscript version 4 |
| 7 Jul 2020 | Author responded | Author comments - Andy Göbel |
| Resubmission - Version 5 | ||
| 7 Jul 2020 | Submitted | Manuscript version 5 |
| Publishing | ||
| 10 Jul 2020 | Editorially accepted | |
| 29 Jul 2020 | Article published | 10.1186/s12885-020-07164-x |
You can find further information about peer review here.